RE:RE:Pharma faces looming patent cliff - seller's market in bio Uber , for some reason has a deep rooted hatred for Onc management. In addition I hear through the grape vine he is the moderator of the yahoo site/ chat board.
In that perspective many of my posts have been removed, delayed or not allowed.
Those who know me & my history on chat sites.
1. I don't hide under multiple names, as some do.
2. I make a strong effort to post relevant/ researched information.
3. yes, I'm guilty of " positive speculation", I do however always preface my points as that.
4. I rearley attack any individual or their opinions. I will however strongly refute any out & out lies or miss- directions people post....at times.
Moving on...
As an example I tried to post a reminder of Mondays ONC participation in a symposium hoasted by Cantor Fitzgerald. This will be available on- line to listen into for all.
Cantor, is one of oncys recent analysts & supporters.
for some reason my comments were " denied" citing possible issues?
BTW, the symposium is scheduled for 11am. Listen in if you can.
Regarding , throwing in the towel & Uber's desire to vote out mangement at the May AGM?
Two separate issues. Both with same answer.
Absolutely 100% agree, phase 3 registration process has taken way longer than expected.
However, in the wait, the following has been accomplished.
1. Aware-1, identified 2 separate " biomarkers" , which will help the success of phase 3.
2. Goblet ( with Roche), has shown well above expectations regarding pancreatic cancer. Leading to a quick FDA fast track designation......Onc now has two phase 3 ready opportunities.
3. The China partner A.N. Has published positive results in their run- in trial. Again more phase 3 pre- work.
4. The Bracelet trial is expected to provide good results this coming June 2-5, at ASCO. Again expected to lead to phase 3 partnership.
5. The CAR-T trial has shown ( very early, preclinical) success..Onc is looking to partner that for further development.
These statements are not pumping, just stating facts. All available on the compnay web site.
So....why would I after holding shares for a very long time, bail out now? When we are possibly within 2-3 months away from decent business development?
My question answers itself. I actually bought more last week!
Regarding voting out management? That would only discredit the value & reputation of the company further.
Check out the details of the management team & BOD.
All very qualified & decades of experience.
if Onc fails it's not because of mangement, but the science itself. Which BTW, no manager can change.
They have delayed phase 3 ( yes we know that), the delays have caused the SP to fall. ( yes we know that).
However, since the onset of phase 3 ( fda approval & recommendations 2018), they have enlisted trials with:
Roche, Pfizer, BMS, Incyte, various cancer institutions around the world.
negotiating a deal?
Again, in compnay investor presentation web site; They say to expect phase 3 trial parameters by secind. Half igpf this year.
That would mean by default a partner & who's co- therapy they would be going with.
take - over , buyout ?
anything is possible.
My bet not until after the June results are released.
long view......
The last quarter of this year will be do or die.
There are ample trials in progress to prove positive or not.
if they don't get Pela to phase 3 , this year. Meaning both MBc & panc failed to be moved forward. Not much left.
enjoy Monday.
have a great week all.